Technology for building antibodies, Antibody

Meditope Biosciences is pioneering the development of next-generation oncology therapeutics through its innovative SnAP (Site-specific novel Antibody Platform) technology. This versatile platform allows for the precise and controlled attachment of various therapeutic payloads, such as proteins, toxins, and radioisotopes, to antibodies. By utilizing a "LEGO-like" conjugation system, Meditope can create complex therapeutic constructs that enhance the specificity and efficacy of cancer treatments. The technology enables the combination of clinically validated components in a manner that maximizes their therapeutic potential, resulting in targeted delivery systems that minimize off-target toxicity.

The company is advancing two key product candidates: MDT-01 ("MeARC") and MDT-02 ("MeKine"). MDT-01 is an antibody-directed radiopharmaceutical designed for treating multiple myeloma, utilizing shortwave radioisotopes to deliver radiation directly to cancer cells. This approach aims to address treatment-resistant cases while reducing collateral damage to healthy tissues. MDT-02 leverages the power of cytokines, specifically a masked form of IL-2, fused to antibodies via cleavable linkers, enhancing tumor specificity and therapeutic efficacy. Together, these products exemplify Meditope's commitment to addressing significant unmet medical needs in oncology through innovative and targeted therapeutic strategies.

United States

Meditope Biosciences, Inc. is in possession of a revolutionary antibody platform technology called “SnAP” (Site-specific, novel, Antibody Platform), which can turn antibodies into a LEGO-like system. The power, elegance, and simplicity of SnAP allows for a broad range of molecules – toxins, proteins, radiolabels, other antibodies – to be ‘snapped’ on or off an antibody with predictability, precision and control. Meditope is using this technology to develop a preclinical pipeline of compelling cancer drugs including two new immuno-oncology product for prostate and bladder cancers.

Meditope Biosciences

Company Details